Posted by Michael Wonder on 10 Feb 2021
Botox (onabotulinumtoxinA) receives FDA approval for paediatric detrusor overactivity associated with a neurologic condition
10 February 2021 - Milestone marks 12th U.S. therapeutic indication for Botox.
Allergan today announced that the U.S. FDA has approved Botox for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in paediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anti-cholinergic medication.
